Anti-PD-1/PD-L1 and anti-PD-1/CTLA-4 therapy had minimal impact on the richness, diversity, and species abundance of the intestinal microbiome of patients with advanced NSCLC, RCC, and melanoma, when comparing baseline and week 12 of treatment. Here, PDCD1 is linked to renal cell carcinoma.